Steve Seedhouse
Managing Director, Biotech Equity Research Cantor Fitzgerald
Seminars
Thursday 31st July 2025
Investment Panel: Attracting Investment & Securing Preclinical Funding for Early-Stage RNA Editing Therapeutic Candidates
9:00 am
• How is RNA editing viewed by investors and what are the directions for growth?
• How to successfully gain funding for preclinical candidates by demonstrating the right data
• What are the hurdles and pitfalls to starting an RNA Editing therapeutics company and what are the timelines, collaborations, and levels of investment required
Thursday 31st July 2025
CEOs’ Fireside Chat: Lessons from RNA Editing’s CEOs on Driving Clinical & Commercial Development to Accelerate RNA Editors to Patients
10:00 am
• Delving into the work of RNA editing’s leading CEOs to understand their perspectives on the field, ongoing journey to success, and directions for future development
• Learnings to apply to your own RNA editing pipeline and business strategy to accelerate translation and achieve commercial viability
